search icon
  • Print
  • ShareThis
  • Text Size
Sort By:  Relevance | Date
Showing results 1 - 10 of 25.
(0.09 second)
Only results matching the refine constraints are displayed. [Clear]
PDF
IDSA Comments to NSABB on Gain-of-Function Risk-Benefit Assessment (PDF)
The Infectious Diseases Society of America (IDSA) is pleased to offer recommendations to the National Science Advisory Board for Biosecurity (NSABB) as it works with Gryphon...
http://www.idsociety.org/.../Letters/IDSA Comments to NSABB RE GOF 081015.pdf - 4 pages

Details | Not yet rated

PDF
IDSA Comments on NIH Strategic Plan (PDF)
Strategic Plan. As biomedical research has become more interdisciplinary, the need for an objective set of NIH-wide principles to guide cross-cutting research topics has...
http://www.idsociety.org/.../IDSA Comments on NIH Strategic Plan 081415.pdf - 3 pages

Details | Not yet rated

PDF
IDSA, PIDS, and HIVMA Comments to NIH to Improve the Impact and Sustainability of Biomedical Research (PDF)
National Institutes of Health’s (NIH) request for information on optimizing funding policies and other strategies to improve the impact and sustainability of biomedical...
http://www.idsociety.org/.../Joint IDSA-PIDS-HIVMA Letter on NIH Sustaining R... - 5 pages

Details | Not yet rated

PDF
IDSA Comments on the Impact of Select Agent Regulations (PDF)
request for information (RFI) concerning the impact of select agent regulations (SAR). IDSA strongly believes that research conducted with select agents and toxins require...
http://www.idsociety.org/.../IDSA comments on the impact of SAR 03-30-15.pdf - 3 pages

Details | Not yet rated

PDF
IDSA Comments to NIH on the Use of a Single IRB for Multi-Site Research Trials (PDF)
10,000 infectious diseases physicians and scientists devoted to patient care, disease prevention, public health, education, and research in the area of infectious diseases. ...
http://www.idsociety.org/.../IDSA Comments on NIH draft central IRB Policy Fi... - 2 pages

Details | Not yet rated

PDF
IDSA Comments to PCORI (PDF)
The Infectious Diseases Society of America (IDSA) represents over 10,000 infectious diseases physicians and scientists devoted to patient care, disease prevention, public...
http://www.idsociety.org/.../Letters/IDSA Comments to PCORI 091114.pdf - 4 pages

Details | Not yet rated

PDF
IDSA Letter to NIH on Informed Consent for Research Use of Clinical Specimens (PDF)
The Infectious Diseases Society of America (IDSA) represents more than 10,000 infectious diseases physicians and scientists devoted to patient care, prevention, public...
http://www.idsociety.org/.../Letters/IDSA Letter to NIH on Informed Consent.pdf - 3 pages

Details | Not yet rated

PDF
IDSA Comments on Institutional Oversight of Life Sciences Dual Use Research of Concern (PDF)
Oversight of Life Sciences Dual Use Research of Concern. As a professional society representing more than 10,000 physicians and scientists involved in a wide range of...
http://www.idsociety.org/.../IDSA Comments on USG Policy for Institutional Ov... - 3 pages

Details | Not yet rated

PDF
IDSA Comments on HHS H5N1 Select Agent Proposal (PDF)
IDSA represents nearly 10,000 infectious diseases physicians and scientists devoted to patient care, prevention, public health, education, and research in the area of...
http://www.idsociety.org/.../IDSA Comments on H5N1 Select Agent Proposal 1214... - 3 pages

Details | Not yet rated

PDF
IDSA Suggests Changes to NIAID Clinical Trials Infrastructure (PDF)
First, to express IDSA leaders’ sincere gratitude for the keynote talk you presented to launch the July 26-27, 2010 Food and Drug Device and Drug Development Research for...
http://www.idsociety.org/.../IDSA letter to Dr. Fauci on clinical trials infr... - 2 pages

Details | Not yet rated

Refine Your Results:
Topic:
Research & InfrastructureResearch & Infrastructure
Letters To AgenciesLetters To Agencies (25)
Emerging Infections & BiothreatsEmerging Infections &... (4)
Antimicrobial ResistanceAntimicrobial Resistance (3)
Workforce & TrainingWorkforce & Training (2)
Antibiotic Development: 10x'20Antibiotic Development: 10x'20 (2)
 
more
Type of information:
Letters To AgenciesLetters To Agencies
Letters to AgenciesLetters to Agencies (25)
LettersLetters (4)
FDA-Related EffortsFDA-Related Efforts (2)
CommentsComments (1)
 
Year:
2015 (5)
2014 (2)
2013 (2)
2012 (4)
2011 (12)
 
Type:
pdfPDF (25)
 
Source:
IDSA WebsiteIDSA Website (25)
 
Powered by Coveo Enterprise Search
Result Page: 1  2  3  [Next]

| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site